MedTrace Logo

Safety Study of Nicardipine to Treat Cerebral Vasospasm

NCT01810302 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2014-08-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if intrathecal nicardipine is safe for the treatment of cerebral vasospasm.

Conditions

  • Cerebral Vasospasm

Interventions

DRUG

Nicardipine hydrochloride

Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.

DRUG

Preservative-free normal saline

Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Spiros L. Blackburn, MD · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01810302 on ClinicalTrials.gov